Small molecule therapeutics that aid in clearing abnormal protein deposits observed in neurodegenerative diseases.
Synthetic oligonucleotides blocking natural degradation of utrophin to treat muscular dystrophy.
Brain penetrating compounds as promising therapeutics for treatment of neurodegenerative disorders.
Novel derivatives of oleic acid effectively inhibiting ferroptosis that could be used for treatment of Friedreich Ataxia, neurodegenerative diseases, and neuropsychiatric diseases.
Two novel monoclonal antibodies were discovered that target pathological conformations of the tau protein. The antibodies were shown in vitro and in vivo to inhibit the spread of pathological tau protein aggregates, which is one of the defining characteristics of AD.
shRNA library of 3 million sequences for identification of small-RNA therapeutic candidates, new targets and pathways, as well as conventional chemical-compound drugs in cell-culture disease models.
Flexible foldable actively multiplexed high density electrode array for mapping brain activity in-vivo
[%brief%]
Method for automatic and unsupervised classification of high-frequency oscillations in physiological recordings.
New compounds identified through high throughput screening which improve mitochondrial function of Friedreich ataxia cells.